14 / 23
Page 58
J Obes Eat Disord, 2017
ISSN: 2471-8203
August 23-24, 2017 | Toronto, Canada
allied
academies
INTERNATIONAL OBESITY, BARIATRIC AND
METABOLIC SURGERY SUMMIT AND EXPO
J Obes Eat Disord, 3:2
DOI: 10.21767/2471-8203-C1-003
Background:
Overweight and obesity are strongly associated
with the development of several chronic diseases in human
including diabetes, cardiovascular disease and high blood
pressure. Flax seed is known as an effective compound for
treatment of obesity due to high content of alpha-linolenic
acid, fiber and lignans.
Objective:
We aim to evaluate the effects of flaxseed
consumption on serum adiponectin, leptin, and weight loss
in overweight or obese women.
Methods:
Arandomizedcontrolledclinicaltrialwasconducted
on 60 patients with overweight or obesity. Participants were
randomly allocated to two groups; a) weight loss diet plus
25 g/day brown milled Flaxseed and b) weight loss diet plus
25 g/day raw powder rice, for 12 weeks. Anthropometric
indices and serum leptin and adiponectin were measured at
baseline and at the end of the intervention.
Findings:
After 12 weeks of intervention, weight, body
mass index (BMI) and waist to hip ratio (WHR) decreased
significantly in flaxseed group but not the controls. Reduction
of waist circumference (WC) (P=0.001) and WHR (P=0.003)
were significantly more in flaxseed group compared to
control group. There was a significant reduction in serum
leptin and an increase in serum adiponectin of flaxseed
group after intervention (P<0.001 for both). Increase of
adiponectin level was significantly more in flaxseed group
compared to the controls (P=0.002).
Conclusion:
Flaxseed consumption could reduce WC and
WHR in a low energy diet. Also it may improve adiponectin
level as an important adipocytokine in regulation of body
composition and weight. So, flax seeds can be used as a
supplement to attenuate central obesity.
e:
shivafaghih@gmail.comFlaxseed consumption could improve adiponectin level and reduce central obesity in overweight or
obese women: A randomized controlled clinical trial
Shiva Faghih and Hoda Ahmadnia
Shiraz University of Medical Sciences, Iran